BioCryst Pharmaceuticals,Inc. (BCRX)

[surf1944]

6:44AM BioCryst Pharm misses by $0.01, misses on revs; announces positive top-line results from its Phase 2a monotherapy BCX4208 gout study (BCRX) 6.18 : Reports Q2 (Jun) loss of $0.23 per share, $0.01 worse than the Thomson Reuters consensus of ($0.22); revenues rose 58.3% year/year to $7.6 mln vs the $15.9 mln consensus. All doses of BCX4208 evaluated met the primary endpoint of the study, including both doses studied in part two. Enrollment in Part 2 was closed after the 240 mg treatment group achieved two efficacy stopping criteria: greater than 4 mg/dL reduction in sUA from baseline, and greater than 60 percent of patients achieving sUA concentration below 6 mg/dL. BCX4208 was generally safe and well-tolerated at all doses evaluated in this study.